This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Palomba, S. Articles by Mastrantonio, P. Search for Related Content PubMed PubMed Citation Articles by Palomba, S. Articles by Mastrantonio, P.

Effect of Estrogen Replacement Plus Low-Dose Alendronate Treatment on Bone Density in Surgically Postmenopausal Women with Osteoporosis

Chair of Obstetrics and Gynecology (S.P., T.S., F.Z.), University of Catanzaro, 88100 Catanzaro, Italy; Departments of Molecular and Clinical Endocrinology and Oncology (F.O., A.C., G.L.), and Gynecology, Obstetrics, and Human Reproduction (C.d.C.), University of Naples "Federico II", 80131 Naples, Italy; Department of Obstetrics and Gynecology (P.M.), University of Messina, 98100 Messina, Italy

Address all correspondence and requests for reprints to: Dr. Stefano Palomba, Via Nicolardi 188, Napoli 80131, Italy. E-mail: . stefanopalomba{at}tin.it

Abstract

This prospective randomized, double-blind, placebo-controlled, clinical trial was performed to evaluate the effectiveness of estrogens plus low-dose alendronate on bone metabolism. A total of 150 surgically postmenopausal women with osteoporosis were randomized in three groups: group A, micronized E2 (2 mg/d) plus standard-dose alendronate (10 mg/d); group B, micronized E2 plus low-dose alendronate (5 mg/d); and group C, micronized E2 plus placebo (one tablet per day). In all women, bone mineral density (BMD) and serum bone metabolism markers were assessed at admission and every 6 months for 2 yr.

After 2 yr, BMD significantly increased compared with baseline in all groups. The percentage BMD change was significantly higher in groups A and B than in group C. The differences in BMD detected between groups A and B were not statistically significant. Since the 6-month follow-up and throughout the study, serum osteocalcin and bone alkaline phosphatase levels and urinary deoxypyridinoline and pyrilinks-D excretion were significantly reduced in all groups. Serum bone alkaline phosphatase levels significantly decreased in groups A and B, without difference between them, in comparison with group C.

In conclusion, in surgically postmenopausal osteoporotic women treated with estrogen replacement, the addition of alendronate at a low dose of 5 mg daily induces a gain of bone mass not significantly different in comparison with that obtained using a standard dose of 10 mg daily.

This article has been cited by other articles:

				S. Palomba, F. Orio Jr., A. Falbo, T. Russo, A. Tolino, and F. Zullo Clomiphene Citrate Versus Metformin as First-Line Approach for the Treatment of Anovulation in Infertile Patients with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3498 - 3503. [Abstract] [Full Text] [PDF]

				S. Palomba, A. Falbo, T. Russo, F. Manguso, A. Tolino, F. Zullo, P. De Feo, and F. Orio Jr. Insulin Sensitivity after Metformin Suspension in Normal-Weight Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3128 - 3135. [Abstract] [Full Text] [PDF]

				S. Palomba, T. Russo, F. Orio Jr, A. Falbo, F. Manguso, T. Cascella, A. Tolino, E. Carmina, A. Colao, and F. Zullo Uterine effects of metformin administration in anovulatory women with polycystic ovary syndrome Hum. Reprod., February 1, 2006; 21(2): 457 - 465. [Abstract] [Full Text] [PDF]

				S. Palomba, F. Orio Jr., A. Falbo, F. Manguso, T. Russo, T. Cascella, A. Tolino, E. Carmina, A. Colao, and F. Zullo Prospective Parallel Randomized, Double-Blind, Double-Dummy Controlled Clinical Trial Comparing Clomiphene Citrate and Metformin as the First-Line Treatment for Ovulation Induction in Nonobese Anovulatory Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4068 - 4074. [Abstract] [Full Text] [PDF]

				S. Palomba, F. Orio Jr., L. G. Nardo, A. Falbo, T. Russo, D. Corea, P. Doldo, G. Lombardi, A. Tolino, A. Colao, et al. Metformin Administration Versus Laparoscopic Ovarian Diathermy in Clomiphene Citrate-Resistant Women with Polycystic Ovary Syndrome: A Prospective Parallel Randomized Double-Blind Placebo-Controlled Trial J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 4801 - 4809. [Abstract] [Full Text] [PDF]

				F. Orio Jr., S. Palomba, T. Cascella, B. De Simone, S. Di Biase, T. Russo, D. Labella, F. Zullo, G. Lombardi, and A. Colao Early Impairment of Endothelial Structure and Function in Young Normal-Weight Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4588 - 4593. [Abstract] [Full Text] [PDF]

				S. Evio, A. Tiitinen, K. Laitinen, O. Ylikorkala, and M. J. Valimaki Effects of Alendronate and Hormone Replacement Therapy, Alone and in Combination, on Bone Mass and Markers of Bone Turnover in Elderly Women with Osteoporosis J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 626 - 631. [Abstract] [Full Text] [PDF]

				S. A. Brown and J. L. Sharpless Osteoporosis: An Under-appreciated Complication of Diabetes Clin. Diabetes, January 1, 2004; 22(1): 10 - 20. [Abstract] [Full Text] [PDF]

				S. L. Greenspan, N. M. Resnick, and R. A. Parker Combination Therapy With Hormone Replacement and Alendronate for Prevention of Bone Loss in Elderly Women: A Randomized Controlled Trial JAMA, May 21, 2003; 289(19): 2525 - 2533. [Abstract] [Full Text] [PDF]

				S. Palomba, F. G. Numis, G. Mossetti, D. Rendina, P. Vuotto, T. Russo, F. Zullo, C. Nappi, and V. Nunziata Raloxifene administration in post-menopausal women with osteoporosis: effect of different BsmI vitamin D receptor genotypes Hum. Reprod., January 1, 2003; 18(1): 192 - 198. [Abstract] [Full Text] [PDF]

				S. Palomba, T. Russo, F. Orio Jr, L. Tauchmanova, E. Zupi, P. L. B. Panici, C. Nappi, A. Colao, G. Lombardi, and F. Zullo Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial Hum. Reprod., December 1, 2002; 17(12): 3213 - 3219. [Abstract] [Full Text] [PDF]

				S. Palomba, F. Orio Jr., M. Morelli, T. Russo, M. Pellicano, C. Nappi, P. Mastrantonio, G. Lombardi, A. Colao, and F. Zullo Raloxifene Administration in Women Treated with Gonadotropin-Releasing Hormone Agonist for Uterine Leiomyomas: Effects on Bone Metabolism J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4476 - 4481. [Abstract] [Full Text] [PDF]